MacroGenics

MGNXPhase 3

MacroGenics is a fully-integrated biopharmaceutical company with a mission to develop life-changing medicines for patients with cancer. The company has built a broad pipeline of investigational product candidates, including its lead bispecific DART® molecule lorigerlimab, and has established strategic collaborations with global pharmaceutical companies. With in-house GMP manufacturing capabilities and a focus on innovative antibody engineering, MacroGenics aims to address significant unmet needs in oncology.

Market Cap

$181.8M

Focus

AntibodiesBiologics

MGNX · Stock Price

USD 2.865.90 (-67.35%)

Historical price data

AI Company Overview

Technology Platform

Proprietary suite of antibody-based platforms including the DART® (bispecific) and TRIDENT® (trispecific) platforms for T-cell engagement, and an ADC platform for antibody-drug conjugates.

Pipeline Snapshot

43 drugs in pipeline, 2 in Phase 3

Drug	Indication	Stage
Margetuximab + Trastuzumab + Physician's choice of chemotherapy.	HER-2 Positive Breast Cancer	Phase 3
enoblituzumab + MGA012 + MGD013	Head and Neck Cancer	Phase 2/3
Enoblituzumab	Prostate Cancer	Phase 2
RAV12 + Gemcitabine	Pancreatic Cancer	Phase 2
Enoblituzumab	Prostate Cancer	Phase 2

Opportunities

Key growth opportunities include the successful clinical development and approval of lorigerlimab in checkpoint-refractory cancers, advancement of its novel ADC pipeline targeting solid tumors, and securing additional strategic partnerships leveraging its DART® and TRIDENT® platforms.

Royalty streams from partnered assets like MARGENZA®, ZYNYZ®, and TZIELD® provide potential for near-term, non-dilutive revenue.

Risk Factors

Primary risks include clinical trial failures for lead assets, intense competition in the immuno-oncology and ADC spaces, potential regulatory setbacks, and reliance on external capital to fund operations until key products are commercialized.

Execution risk in managing a diverse pipeline and competing for talent with larger biopharma companies are also notable challenges.

Competitive Landscape

MacroGenics competes with large pharmaceutical companies with extensive oncology portfolios (e.g., Merck, Bristol-Myers Squibb, Roche) and biotechnology firms focused on bispecifics and ADCs. Its differentiation is rooted in its proprietary antibody engineering platforms (DART®, TRIDENT®) designed to create molecules with unique properties, and its fully integrated model which includes in-house GMP manufacturing capabilities.